Abstract |
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
|
Authors | Yon Ju Ryu, Eun Mi Chun, Soon Nam Lee, Sung Shin Shim |
Journal | Korean journal of radiology
(Korean J Radiol)
2014 Mar-Apr
Vol. 15
Issue 2
Pg. 300-4
ISSN: 2005-8330 [Electronic] Korea (South) |
PMID | 24642811
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Quinazolines
- Gefitinib
|
Topics |
- Antineoplastic Agents
(adverse effects)
- Brain Neoplasms
(secondary)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, secondary)
- Cysts
(chemically induced)
- Female
- Gefitinib
- Humans
- Lung
(pathology)
- Lung Diseases
(chemically induced)
- Lung Diseases, Interstitial
- Lung Neoplasms
(drug therapy)
- Middle Aged
- Quinazolines
(adverse effects)
|